IRADIMED CORPORATION IRMD
At closeNov 5, 2026, 4:20 AM EST
Pre-market · Nov 5, 4:20 AM ET
- YTD
- -8.94%
- 1 year
- +2.12%
- Market cap
- 1.13B
- Revenue (ttm)
- 89.34M
- Profit margin
- 26.85%
- EPS (ttm)
- 1.87
- Shares out
- 12.79M
- P/E ratio
- 47.37
- Forward P/E
- 36.35
- Dividend
- 0.80 (1.01%)
- Ex-dividend date
- Aug 13, 2026
- YTD return
- -8.94%
- 1-year return
- +2.12%
- Volume
- 184.05K
- Avg volume
- 121.28K
- Open
- 82.73
- Previous close
- 81.11
- Day's range
- 82.73 – 89.17
- 52-week range
- 76.35 – 107.90
- Beta
- 0.94
- Analysts
- Buy
- Price target
- 118.00 (+33.2%)
- Earnings date
- Feb 9, 2027
5D -4.52 (-5.39%)
Key statistics
- Enterprise value
- 973.96M
- PEG ratio
- 0.00
- Price / sales
- 12.68
- Price / book
- 10.64
- Dividend yield
- 0.99%
- Payout ratio
- 41.18%
- Revenue growth
- 14.20%
- Free cash flow
- 17.53M
- Total cash
- 63.29M
- Total debt
- 0
- Return on equity
- 23.42%
- Short % of float
- 8.08%
- 50-day average
- 85.37
- 200-day average
- 92.32
Analyst view
Consensus: buy
- Target (low)
- 116.00
- Target (mean)
- 118.00
- Target (high)
- 120.00
- Strong buy0
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 9, 2027
Expected Feb 9, 2027. Consensus EPS estimate 0.60.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 9, 2027 | Dec 30, 2026 | 0.593 | — | — | — |
| Oct 30, 2026 | Sep 30, 2026 | 0.55 | 0.55 | 0.00 | 0.00% |
| Jul 31, 2026 | Jun 30, 2026 | 0.44 | 0.46 | +0.02 | +4.55% |
| May 1, 2026 | Mar 31, 2026 | 0.45 | 0.49 | +0.04 | +8.89% |
| Feb 10, 2026 | Dec 31, 2025 | 0.49 | 0.54 | +0.05 | +10.20% |
| Nov 3, 2025 | Sep 30, 2025 | 0.48 | 0.47 | -0.01 | -2.08% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 22, 2026 | Needham | init | — | Hold |
| Apr 2, 2026 | Freedom Broker | init | — | Buy |
| Feb 14, 2025 | Roth MKM | reit | Buy | Buy |
| Aug 2, 2024 | Roth MKM | main | Buy | Buy |
| Aug 2, 2021 | Roth Capital | main | — | Buy |
| Jul 31, 2017 | Roth Capital | up | Neutral | Buy |
About IRADIMED CORPORATION
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- iradimed.com
News
What iRadimed (IRMD) Said on Its Q3 Earnings Call 
IRADIMED CORPORATION (IRMD) Q3 2026 Earnings Call Transcript 
iRadimed Q3 2026 Earnings Call Transcript 
iRadimed Q3 Adj. EPS $0.55, Inline, Sales $24.203M Beat $23.467M Estimate 
iRadimed Lowers FY2026 Adj EPS Guidance from $2.09-$2.24 to $2.07-$2.11 vs $2.11 Est; Narrows FY2026 Sales Guidance from $91.000M-$96.000M to $91.600M-$93.100M vs $92.133M Est 
iRadimed Sees Q4 Adj EPS $0.57-$0.61 vs $0.63 Est; Sees Sales $25.000M-$26.500M vs $26.233M Est 
IRADIMED CORPORATION Reports Third Quarter 2026 Financial Results
Your note
Sign in to keep a note on IRMD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLEN MONTY K | Director | Sale | Sep 2, 2026 | 19,581 |
| CHIPRIN JEFF | Officer | Conversion of Exercise of derivative security | Dec 10, 2025 | 687 |
| GLENN JOHN F | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 17, 2026 | 11,937 |
| HAWKINS JAMES B | Director | Conversion of Exercise of derivative security | Dec 10, 2025 | 29,647 |
| SCHAREN-GUIVEL HILDA FREDERIQUE | Director | Sale | Jun 3, 2026 | 5,598 |
| SUSI ROGER E | Chief Executive Officer | Sale | May 31, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.57% | 967,825 | 85.73M | Jun 29, 2026 |
| Kayne Anderson Rudnick Investment Management LLC | 3.10% | 396,982 | 35.16M | Jun 29, 2026 |
| Renaissance Technologies, LLC | 3.08% | 394,412 | 34.94M | Jun 29, 2026 |
| Copeland Capital Management, LLC | 2.99% | 382,013 | 33.84M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 2.85% | 364,937 | 32.33M | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 2.49% | 318,680 | 28.23M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.07% | 264,366 | 23.42M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.65% | 211,269 | 18.71M | Sep 29, 2026 |
| Virtus Equity Trust-Virtus KAR Small-Cap Growth Fund | 1.07% | 136,772 | 12.12M | Jun 29, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 0.91% | 116,902 | 10.36M | Jun 29, 2026 |
| JNL Series Trust-JNL Multi-Manager Small Cap Growth Fund | 0.80% | 102,570 | 9.09M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.72% | 92,567 | 8.20M | Aug 30, 2026 |